Fujita M, Sato Y
Chiyoda Technol Corporation, 3681 Narita-cho Oarai-machi, Higashiibaraki-gun Ibaraki-ken, 311-1313, Japan.
Radiat Prot Dosimetry. 2003;105(1-4):123-8. doi: 10.1093/oxfordjournals.rpd.a006206.
For 60Co (Type S) and 54Mn (Type M), for which the whole-body content can be measured, it is possible to minimise the errors of the estimated effective doses caused by uncertainty of the activity median aerodynamic diameter (AMAD) by assuming the AMAD to be 5 microm and by measuring the body content on day 5 after inhalation. For the radionuclides to be measured in the lung content, e.g. 239Pu (Type S), it may be necessary to estimate the AMAD, because the lung burdens on any day are not always proportional to the whole-body content which reflects the effective doses. There is no problem in assuming the AMAD to be 5 microm for external counting and for urinalysis of Type F compounds, because of the rapid absorption of such compounds into the blood and the same biokinetics. The breathing rate is assumed to be 1.2 m3 h(-1).
对于全身含量可测量的60Co(S型)和54Mn(M型),通过假设活度中位空气动力学直径(AMAD)为5微米,并在吸入后第5天测量身体含量,可以将由AMAD不确定性引起的估计有效剂量误差降至最低。对于要在肺部含量中测量的放射性核素,例如239Pu(S型),可能有必要估计AMAD,因为任何一天的肺部负荷并不总是与反映有效剂量的全身含量成比例。对于F型化合物的体外计数和尿液分析,假设AMAD为5微米没有问题,因为此类化合物会迅速吸收到血液中且具有相同的生物动力学。呼吸速率假设为1.2立方米/小时。